Company intelligence / Profile preview

AbViro LLC

Bethesda, Maryland, United Statesabvacc.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

AbViro’s lead candidate, AV1, is a fully human monoclonal antibody targeting the dengue virus envelope. It completed a Phase 1 safety study and entered a US NIH-funded Phase IIa challenge trial in early 2025 with the goal to become the first FDA-approved treatment for dengue fever. The product is orally administered and aims to address an unmet need where current care is only supportive. No published efficacy results yet; safety established in healthy volunteers.

Therapeutic areas: Infectious Diseases
Modalities: Monoclonal antibodies (fully human mAbs)
Industry: Biotech

Drug pipeline

2 assets

AV-1

1 more asset in the full pipeline.

Partnerships

National Institutes of Health/NIAID – funding and collaboration on clinical trials for AV1 against dengue

Beyond the preview

Go deeper on AbViro LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AbViro LLC.